GET DAILY SIGNALSINDP Stock: Indaptus Therapeutics' Decoy20 and the Promise of Multi-Targeted Immunotherapy
Key Takeaways
- INDP is the Nasdaq-listed common stock of Indaptus Therapeutics, Inc., a clinical-stage biotechnology company based in New York.
- The company is developing a novel, systemically administered anti-cancer and anti-viral immunotherapy platform centered on its lead candidate, Decoy20.
- Indaptus is pre-revenue and unprofitable, with its future value tied largely to the success of ongoing clinical trials and regulatory milestones.
- Its technology uses attenuated, killed, non-pathogenic Gram-negative bacteria designed to activate both innate and adaptive immune responses.
- As a clinical-stage biotech, INDP carries significant development, financing, and regulatory risk.
Getting Started with INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing new immunotherapy approaches for cancer and viral infections. Trading on the Nasdaq under the ticker INDP, the company attracts investor attention because of its distinctive approach to activating the immune system and its early-stage pipeline built around a lead candidate known as Decoy20. Like many early-stage biotechs, Indaptus does not yet generate product revenue; its investment profile is driven primarily by clinical progress, scientific data, and its ability to fund continued development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Company’s Technology and Pipeline
Indaptus Therapeutics is headquartered in New York, New York, and operates within the healthcare and biotechnology sector. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics in August 2021. Its business model is typical of a clinical-stage biopharmaceutical company: it invests heavily in research and development to advance drug candidates through preclinical studies and clinical trials, with the goal of ultimately seeking regulatory approval and commercialization.
The core of Indaptus' technology is its patented "Decoy" platform. The approach is based on the hypothesis that effectively fighting tumors and viral infections requires a multi-targeted package of immune-activating signals delivered safely by intravenous administration. The platform uses single strains of attenuated and killed, non-pathogenic Gram-negative bacteria engineered to reduce toxicity when given intravenously while retaining the ability to prime or activate key components of both the innate and adaptive immune systems.
The company's lead clinical candidate is Decoy20. In preclinical models, the Decoy technology has demonstrated broad anti-tumor activity and durable responses, including synergy with existing therapeutic classes such as checkpoint inhibitors, targeted antibody therapies, and chemotherapy. The company has also reported single-agent preclinical activity against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
Because Indaptus has no commercialized products, its primary "revenue" sources do not yet exist; instead, the company funds operations through equity financings. Its financial profile is defined by research and development expenses, general and administrative costs, and recurring net losses, which are common for companies at this stage of development.
What Draws Attention to INDP
Investors monitor INDP primarily for its scientific differentiation and pipeline potential. The company's platform attempts to address a central challenge in immunotherapy: triggering a broad, multi-targeted immune response rather than relying on a single pathway. If validated in humans, this mechanism could offer a new treatment approach for advanced solid tumors and certain chronic viral infections, areas with substantial unmet medical need. From what I see, this sets it apart in a crowded field.
The lead program, Decoy20, has advanced into human testing. In May 2022, the U.S. Food and Drug Administration (FDA) cleared the company's Investigational New Drug (IND) application, and in December 2022 Indaptus initiated an open-label, multi-center Phase 1 clinical trial in patients with advanced solid tumors. The study is designed to assess safety, tolerability, dosing, and early signs of clinical activity. For a pre-revenue biotech, progression through clinical milestones is the principal driver of long-term value.
Indaptus' market position is that of an emerging innovator competing in the broader oncology and antiviral immunotherapy landscape. Its competitive advantages rest on intellectual property and a differentiated mechanism of action, though it remains far smaller and less established than many larger biopharmaceutical peers.
Navigating the Risks
Investing in INDP involves considerable risk. As a clinical-stage company with a limited operating history, Indaptus is not profitable and has repeatedly disclosed substantial doubt about its ability to continue as a going concern without additional capital. It relies on equity financings to fund operations, which can dilute existing shareholders.
Clinical development is lengthy, expensive, and uncertain. Decoy20 may fail to demonstrate adequate safety or efficacy in human trials, or regulatory authorities may require additional studies, delaying or preventing approval. The company also faces competition from larger, better-capitalized firms pursuing cancer and antiviral immunotherapies, as well as the risk of technological disruption from alternative treatment approaches.
Additional considerations include the company's small workforce, its dependence on protecting proprietary technology, and broader healthcare regulatory and compliance obligations. Because the company generates no product revenue, its financial performance does not follow the patterns investors typically expect from commercial-stage businesses.
Using AI Tools for Biotech Analysis
In my own research, I frequently rely on Tickeron’s AI Screener to quickly filter biotech names by fundamentals, volatility, and AI signals. It helps surface comparable ideas without spending hours on manual screens, which is especially useful when evaluating early-stage names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
INDP saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for INDP moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 41 similar instances where the indicator exited the overbought zone. In 39 of the 41 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INDP as a result. In 87 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INDP turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 48 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The 50-day moving average for INDP moved above the 200-day moving average on October 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDP advanced for three days, in 167 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
INDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 66 of 90 cases where INDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. INDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.898) is normal, around the industry mean (3.498). P/E Ratio (-0.933) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INDP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement